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Abstract
Repeated administration of antipsychotic drugs induces a sensitization-like or tolerance-like effect
in many behavioral tasks, including the conditioned avoidance response (CAR) and the
phencyclidine (PCP)-induced hyperlocomotion, two rodent models with high predictive validity
for antipsychotic activity. This study investigated the impacts of contextual and behavioral
variables on the expression of clozapine tolerance using a recently validated across-model transfer
paradigm (Zhang and Li, 2012). Male Sprague-Dawley rats were first repeatedly treated with
clozapine (2.5–10.0 mg/kg, sc) in the CAR model or PCP (1.6 mg/kg, sc)-induced
hyperlocomotion model for five consecutive days. They were then tested for the expression of
clozapine tolerance in another model for another five days. Finally, all rats were switched back to
the original model and tested again for the expression of clozapine tolerance. When tested in the
PCP model, rats previously treated with clozapine in the CAR model did not show an immediate
weaker inhibition of PCP-induced hyperlocomotion than those treated with clozapine for the first
time, but showed a significantly weaker inhibition over time. In contrast, when tested in the CAR
model, rats previously treated with clozapine in the PCP model showed an immediate weaker
disruption of avoidance response than those treated with clozapine for the first time, but this
weaker effect diminished over time. These results suggest that the expression of clozapine
tolerance is strongly modulated by the test environment and/or selected behavioral response.
Clozapine tolerance and its situational specificity may be related to the drug’s low extrapyramidal
motor side effect, its superior therapeutic efficacy and/or emergence of clozapine withdrawal
syndrome.
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1. Introduction
Clozapine (CLZ) is the prototypical atypical antipsychotic drug with superior efficacy in
treating the negative symptoms (e.g. social withdrawal, anhedonia) and cognitive deficits
(e.g. attentional deficits) associated with schizophrenia, and patients who respond poorly to
other antipsychotic medications [2–5]. Animal studies find that CLZ differs from other
antipsychotics in many ways. For example, repeated treatment of haloperidol elicits
dopamine supersensitivity (up-regulation of D2 High receptors), whereas repeated treatment
of CLZ has little effect on D2 High up-regulation [6, 7]. Neuroanatomically, CLZ, but not
haloperidol, shows greater selectivity for the mesolimbic dopamine system than for the
nigrostriatal dopamine system [8, 9]. Behaviorally, repeated treatment of haloperidol,
olanzapine and risperidone tends to cause a sensitization [1, 10–12], whereas repeated CLZ
causes a tolerance [11, 13]. For instance, in a motor function and attention test, Stanford and
Fowler [14] reported that CLZ-treated rats exhibited tolerance to the drug’s suppressive
effect on the amount of time that rats were in contact with a force-sensing target disk. In
contrast, haloperidol-treated rats displayed little tolerance on this measure. In a fixed ratio 5
lever pressing test, Trevitt et al. [15] found that both haloperidol and CLZ significantly
suppressed lever pressing. However, with repeated injections, haloperidol enhanced its
suppression, while CLZ decreased it. In a lever pressing for food reward task, Varvel et al.
[16] and Villanueva and Porter [17] also found that repeated haloperidol produced a
significant increase in response duration, while repeated CLZ produced a decrease. CLZ-
induced tolerance has also been observed in a drug discrimination task [18, 19].
The conditioned avoidance response (CAR) and phencyclidine (PCP)-induced
hyperlocomotion are two tests commonly used to study antipsychotic drugs. Both tests have
high predictive validity for antipsychotic efficacy, as acute administration of antipsychotic
drugs, but not anxiolytics or antidepressants selectively disrupts avoidance response, and
suppresses PCP-induced hyperlocomotion [20–25]. In recent years, we have examined the
long-term consequences of repeated CLZ treatment in both tests. First, rats are repeatedly
treated with different doses of CLZ for 5 days then their avoidance responses and PCP-
induced hyperlocomotion are recorded. This period is termed the induction phase. Two days
later, all rats are given a challenge dose of CLZ (5.0 mg/kg) to assess the expression of CLZ
tolerance (termed the expression phase). In the CAR model [11, 13], we found that although
repeated administration of CLZ produces an inhibition of avoidance responses persistently
during the induction phase (no apparent tolerance), in the expression phase when all rats are
challenged with a low dose of CLZ, rats previously treated with CLZ made significantly
more avoidances than those who are treated with this drug for the first time, indicative of
CLZ tolerance. Similarly, in the PCP hyperlocomotion model, repeated CLZ treatment dose-
dependently and persistently inhibits PCP-induced hyperlocomotion in the induction phase
(no apparent tolerance) [23], but exhibits a tolerance effect in the expression phase as rats
previously treated with CLZ have a weaker inhibition of PCP-induced hyperlocomotion than
those treated with CLZ for the first time. The overall pattern of CLZ effect in both models is
in sharp contrast to the effects of haloperidol, olanzapine and risperidone which cause a
sensitization [1, 11, 13].
Despite being widely demonstrated, experimental conditions that govern the expression of
CLZ tolerance are still poorly understood. For example, the extent to which the expression
of CLZ tolerance is modulated by contextual cues and behavioral variables is not known.
How CLZ’s action on avoidance responses and on PCP-induced hyperlocomotion, in turn,
influences the rate and extent of its tolerance development is also not known. In this study,
we examined how the environmental cues and behavioral responses affect the expression of
CLZ tolerance using a novel across-model transfer paradigm [1, 26]. Our general approach
was to repeatedly treat animals with CLZ in one model to induce a tolerance process, then to
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test its expression in another model, and finally to retest its expression back in the original
model. We recently used this paradigm and determined that the expression of haloperidol
and olanzapine sensitization in the CAR and PCP models is strongly influenced by test
environment and/or selected behavioral response [1]. This study extended this line of
research into CLZ. If CLZ tolerance results from inevitable neurobiological adaptations
produced by the direct pharmacological actions of the drug, it should persist into another
model. However, if the contextual cues and behavioral responses associated with different
models have a powerful control on the expression of CLZ tolerance, it should not be
detectable when the model is changed.
2. Materials and Methods
2.1. Animals
Adult male Sprague-Dawley rats (226–250g upon arrival, Charles River, Portage, MI) were
used. They were housed two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent
polycarbonate cages under 12-hr light/dark conditions (light on between 6:30 am and 6:30
pm). Room temperature was maintained at 22±1°C with a relative humidity of 45–60%.
Food and water was available ad libitum. Animals were allowed at least one week of
habituation to the animal facility before being used in experiments. All procedures were
approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.
2.2. Drugs
Clozapine (CLZ, gift from NIMH drug supply program) was dissolved in 1.2% glacial acetic
acid in distilled sterile water [11, 27]. Phencyclidine hydrochloride (PCP, gift from the
NIDA Chemical synthesis and Drug Supply Program) was dissolved in 0.9% saline. All
drugs were administrated subcutaneously in a volume of 1.0 ml/kg body weight. In the first
experiment (from CAR to PCP), we tested three doses of CLZ (2.5, 5.0, 10.0 mg/kg) to
assess the possible dose-dependent nature of CLZ tolerance. These doses of CLZ produce a
reliable disruption on avoidance responding and inhibit the PCP-induced hyperlocomotion
[23, 24]. Furthermore, CLZ at 5.0 and 10.0 mg/kg gives rise to a clinically comparable range
(40%–60%) of striatal dopamine D2 occupancy [27]. Based on findings from the first
experiment and our previous work [23], we tested CLZ at 5.0 mg/kg in the second
experiment (from PCP to CAR). The dose of PCP (1.6 mg/kg, sc) was based on our own
study [1] and others [28].
2.3. Apparatus
2.3.1. Two-way avoidance conditioning apparatus—Eight identical two-way shuttle
boxes custom designed and manufactured by Med Associates (St. Albans, VT) were used.
Each box was housed in a ventilated, sound-insulated isolation cubicle (96.52 cm W × 35.56
cm D × 63.5 cm H). Each box was 64 cm long, 30 cm high (from grid floor), and 24 cm
wide, and was divided into two equal-sized compartments by a partition with an arch style
doorway (15 cm high × 9 cm wide at base). A barrier (4 cm high) was placed between the
two compartments, so the rats had to jump from one compartment to the other. The grid
floor consisted of 40 stainless-steel rods with a diameter of 0.48 cm, spaced 1.6 cm apart
center to center, through which a scrambled footshock (Unconditioned stimulus, US, 0.8
mA, maximum duration: 5 s) was delivered by a constant current shock generator (Model
ENV-410B) and scrambler (Model ENV-412). The rat location and crossings between
compartments were monitored by a set of 16 photobeams (ENV-256-8P) affixed at the
bottom of the box (3.5 cm above the grid floor). Illumination was provided by two
houselights mounted at the top of each compartment. The conditioned stimulus (CS, i.e. 76
dB white noise) was produced by a speaker (ENV 224 AMX) mounted on the ceiling of the
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cubicle, centered above the shuttle box. Background noise (approximately 74 dB) was
provided by a ventilation fan affixed at the top corner of each isolation cubicle. All training
and testing procedures were controlled by Med Associates programs running on a computer.
2.3.2. Motor activity monitoring apparatus—Sixteen activity boxes were housed in a
quiet room. The boxes were 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages,
which were similar to the home cages but were each equipped with a row of 6 photocell
beams (7.8 cm between two adjacent photobeams) placed 3.2 cm above the floor of the
cage. A computer detected the disruption of the photocell beams and recorded the number of
beam breaks. All experiments were run during the light cycle.
2.4. Experiments
2.4.1. Experiment 1: Transferability of CLZ tolerance from the CAR model to
the PCP hyperlocomotion model and back to the CAR model—This experiment
examined whether the tolerance induced by repeated CLZ treatment in the CAR model
expressed in the PCP-induced hyperlocomotion model. The experiment comprised the
following three phases: Avoidance training/repeated CLZ treatment in the CAR, tolerance
expression test in the PCP hyperlocomotion model, and tolerance expression retest back in
the CAR model.
Avoidance training/repeated CLZ treatment in the CAR: Eighty-eight rats (in 2 batches)
were first handled and habituated to the CAR boxes for 2 days (20 min/day). They were then
trained for conditioned avoidance responding for a total of 10 sessions over a 2-week period.
Each session consisted of 30 trials, with inter-trial intervals randomly varying between 30
and 60 s. Every trial started with a presentation of a white noise (CS) for 10 s, followed by a
continuous scrambled foot shock (0.8 mA, US, maximum duration = 5 s) on the grid floor. If
a subject crossed from one compartment into the other within the 10 s of CS presentation, it
avoided the shock and this shuttling response was recorded as avoidance. If the rat remained
in the same compartment for more than 10 s and made a crossing only after receiving the
footshock, this response was recorded as escape. If the rat did not switch compartments
during the entire 5 s presentation of the shock, the trial was terminated and escape failure
was recorded. The total number of avoidance responses was recorded for each session.
At the end of the training session, 65 rats reached the training criterion (>70% avoidance in
each of the last 2 sessions). They were first matched on avoidance performance on the last
training day (pre-drug) to create blocks of rats that were approximately equal in
performance. Within each block, they were then randomly assigned to one of four groups:
CLZ 2.5 mg/kg (n = 8), CLZ 5.0 mg/kg (n = 8), CLZ 10.0 mg/kg (n = 9), and vehicle (n =
40), and tested daily under the CS-only (no shock, 30 trials per session) condition for 5
consecutive days. The CS-only condition was used to control the possible confound of
number of shocks received and to exclude any possible relearning effect caused by the
presence of the US, as employed in our previous studies [1, 11]. On each test day, rats were
first injected with CLZ or vehicle (sterile water), and tested 1 h later.
Tolerance expression test in the PCP hyperlocomotion model: One day after the last
CAR drug test, rats were placed in the motor activity testing boxes for 30 min for
habituation. On Day 2, rats that were previously treated with vehicle (n = 40) during the
CAR tests were randomly assigned to five groups: three groups (n=8) received CLZ
followed by PCP (VEH-CLZ 2.5+PCP; VEH-CLZ 5.0+PCP; and VEH-CLZ 10.0+PCP),
and two groups (n=8) received sterile water followed by PCP or saline (VEH-VEH+PCP
and VEH-VEH+VEH). Rats that had been previously treated with CLZ in the CAR model
received the same CLZ treatment as before followed by PCP (CLZ 2.5-CLZ 2.5+PCP; CLZ
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5.0-CLZ 5.0+PCP and CLZ 10.0-CLZ 10.0+PCP). During each motor activity test session,
rats were first injected with CLZ or sterile water. Immediately after injection, they were
placed in the boxes for 30 min. At the end of the 30-min period, rats were taken out and
injected with either 0.9% saline or PCP (1.6 mg/kg, sc) and placed back in the boxes for
another 60 min. Motor activity was measured in 5 min intervals throughout the entire 90-
min testing session. This procedure was repeated for another 4 days (a total of 5 test days).
Tolerance expression retest in the CAR: One day after the last PCP hyperlocomotion test,
all rats were brought back to the CAR boxes and retrained drug-free under the CS-only
condition for one session and under the CS-US condition for another session to bring their
avoidance back to the pre-drug level. A final challenge test for the expression of CLZ
tolerance originally induced in the CAR model (e.g. CLZ 5.0-CLZ 5.0+PCP group) and
newly induced in the PCP model (e.g. VEH-CLZ 5.0+PCP group) was conducted 24 h after
the retraining session during which all rats were injected with CLZ 5.0 mg/kg and tested for
avoidance performance in the CS-only condition (30 trails) 1 h later. Table 1 summarizes the
experimental procedure and groups at different phases of the experiment.
2.4.2. Experiment 2: Transferability of CLZ-induced tolerance effect from the
PCP hyperlocomotion model to the CAR model and back to the PCP model—
This experiment was a mirror experiment to Experiment 1 in the sense that it examined the
opposite direction of CLZ tolerance transfer. Specifically, we examined whether CLZ
tolerance effect induced in the PCP hyperlocomotion model extended into the CAR model
and back to the original PCP model. The entire experiment was comprised of the following
three phases: Avoidance training and repeated CLZ treatment in the PCP hyperlocomotion
model, tolerance test in the CAR, and tolerance retest back in the PCP hyperlocomotion
model.
Avoidance training and repeated CLZ treatment in the PCP hyperlocomotion model:
Fifty rats were first handled and habituated to the avoidance conditioning apparatus for two
days (20 min/day), and then trained for a total of ten sessions over a two-week period to
acquire conditioned avoidance response. At the end of the training phase, 44 rats that had
reached the training criterion (>70% avoidance in each of the last 2 sessions) were used in
the PCP test. They were randomly assigned to the following three groups: CLZ 5.0 mg/kg (n
= 9), PCP (n = 18) and vehicle (n = 17). On Day 1, rats were habituated in the motor activity
boxes for 30 min. On Day 2, rats were first injected with CLZ 5.0 mg/kg or sterile water and
then immediately placed in the boxes for 30 min. At the end of the 30-min period, they were
taken out and injected with PCP (1.6 mg/kg) or saline and placed back in the boxes for
another 60 min. This procedure was repeated for another 4 days (a total of 5 test days).
Tolerance expression test in the CAR: One day after the last (5th) PCP hyperlocomotion
test, all rats were given a CAR retraining under the CS-US condition session to bring their
avoidance back to the pre-drug level. One day later, the tolerance expression tests were
conducted. During each test session, rats that were previously treated with CLZ in the PCP
tests were still treated with CLZ 5.0 mg/kg (CLZ 5.0+PCP-CLZ 5.0, n = 9). Rats in the PCP
or VEH group were randomly split into two groups injected with either CLZ (5.0 mg/kg, sc)
or sterile water, respectively. Thus four new groups were formed: VEH+PCP-VEH (n = 9),
VEH+PCP-CLZ 5.0 (n = 9), VEH+VEH-VEH (n = 8) and VEH+VEH-CLZ 5.0 (n = 9). All
rats were tested for avoidance performance in the CS-only condition for 30 trials 1 h after
injection. This procedure was repeated for another 4 days.
Tolerance expression retest in the PCP hyperlocomotion model: One day after the
tolerance assessment in the CAR, a final tolerance expression retest was conducted. All rats
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were first injected with CLZ 5.0 mg/kg and then immediately placed in the motor activity
boxes for 30 min. At the end of the 30-min period, rats were taken out and injected with
PCP (1.6 mg/kg) and placed back in the boxes for another 60 min. Motor activity was
measured in 5 min intervals throughout the entire 90-min testing session. Table 2
summarizes the experimental procedure and groups at different phases of the experiment.
2.5. Statistical Analysis
All data were expressed as mean ± SEM. Data from the five drug test sessions (e.g.
avoidance response and PCP-induced motor activity) were analyzed using a split-plot
analysis of variance (ANOVA) with the between-subjects factor being drug group and the
within-subjects factor being test day. One-way ANOVA followed by post hoc Tukey’s HSD
tests was used to compare group difference on specific days when more than three groups
were involved, and planned samples t tests were used to compare two groups. For all
comparisons, significant difference was assumed at p < 0.05, and all data was analyzed
using SPSS version 19.
3. Results
3.1. Experiment 1: Transferability of CLZ-induced tolerance from the CAR model to the
PCP hyperlocomotion model and back to the CAR model
Repeated CLZ treatment disrupted avoidance response in a dose-dependent
fashion—Figure 1 shows the mean number of avoidance responses made by rats in the four
groups during the five drug test sessions. A spilt-spot ANOVA revealed a main effect of
group, F (3, 61) = 90.369, p < 0.001, and a significant group × test day interaction, F (12,
244) = 3.218, p < 0.001. Post hoc Tukey’s HSD tests show that all three CLZ groups made
significantly fewer avoidance responses than the VEH group, ps < 0.001, and the CLZ 5.0
and CLZ 10.0 groups also had significantly lower avoidance than the CLZ 2.5 group, all ps
≤ 0.05. One-way ANOVAs on each test day revealed that all three CLZ groups had
significantly lower avoidance than the VEH group on all 5 days, ps < 0.001. In addition, the
CLZ 10.0 group had significantly lower avoidance than the CLZ 2.5 group on all 5 days, ps
< 0.05, and CLZ 5.0 group also had significantly lower avoidance than the CLZ 2.5 group
on the first two days, ps < 0.05. It appears that the high dose CLZ (10.0 mg/kg) and the low
dose CLZ (2.5 mg/kg) groups maintained their disruption over time, and the medium dose
group (5.0 mg/kg) showed a progressive across-session decrease in its disruption. However,
repeated measures ANOVA on the CLZ 5 group did not find this change over time to be
statistically significant, p = 0.061.
CLZ tolerance did not manifest in the PCP hyperlocomotion model on the first
day, but emerged after 5 days of testing—On the habituation day, all rats were
placed in the motor activity boxes for 30 min with no drug treatment. One-way ANOVA
showed no main effect of group, F (7, 57) = 0.960, p = 0.469, indicating that all groups had
the equal level of spontaneous motor activity (data not shown).
On the first day of the PCP hyperlocomotion test, CLZ decreased the spontaneous motor
activity (as measured in the first 30 min after CLZ but before PCP injection). One-way
ANOVA revealed a main effect of group, F (7, 57) = 15.699, p < 0.001. Post hoc tests
showed that 6 CLZ groups had consistently lower motor activity than the two VEH groups,
ps < 0.05 (Fig. 2A). In the 60 min after PCP injection, CLZ decreased the PCP-induced
increase in motor activity as the three groups that received CLZ for the first time in this
model showed significantly lower motor activity than the VEH-VEH+PCP group, ps < 0.05
(Fig. 2B). More importantly, when each pair of CLZ groups at the three dosage levels was
compared (e.g. CLZ 5.0-CLZ 5.0+PCP group vs. VEH-CLZ 5.0+PCP group based), no
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significant difference was found, ps > 0.05, indicating no expression of CLZ tolerance on
the first day in the PCP-induced hyperlocomotion model.
Throughout the 5 test days, all 6 CLZ groups consistently showed significantly lower motor
activity in the first 30 min period than the two VEH groups, ps < 0.05 (data not shown). To
examine the time course of the expression of CLZ tolerance in the PCP hyperlocomotion
model, we analyzed the 60-min motor activity data using a split-plot ANOVA with drug
dose (2.5, 5.0, 10.0 mg/kg) and prior treatment (CLZ or VEH in the CAR) as two between-
subjects factors, and test day as the within-subjects factor. This analysis revealed a main
effect of drug dose, F (2, 43) = 3.877, p = 0.028, and a main effect of prior treatment
condition, F (1, 43) = 13.784, p = 0.001, and a main effect of day, F (4, 172) = 6.433, p <
0.001, indicating that prior CLZ treatment in the CAR model made CLZ less effective in
inhibiting the PCP-induced hyperlocomotion, a clear sign of tolerance. We further compared
each pair of CLZ groups separately to determine the dose-dependence of CLZ tolerance
(Fig. 3B–3D). At 10.0 mg/kg, rats previously treated with CLZ in the CAR (i.e. CLZ 10.0-
CLZ 10.0+PCP) had significantly higher motor activity than those treated with CLZ for the
first time in this model (i.e. VEH-CLZ 10.0+PCP). There was a main effect of group, F (1,
15) = 11.153, p = 0.004, a main effect of test day, F (4, 60) = 3.481, p = 0.013, but no
significant interaction between the two, F (4, 60) = 1.052, p = 0.388. Planned two group
comparisons on each test day showed that the CLZ 10.0-CLZ 10.0+PCP group had a
significantly higher level of motor activity than the VEH-CLZ 10.0+PCP group on day 2, p
= 0.010, day 4, p = 0.006, and day 5, p = 0.020, suggesting a clear manifestation of tolerance
at this dose. In contrast, the tolerance effect by CLZ at 2.5 and 5.0 mg/kg in the CAR was
less evident. Under both conditions, the main effects of group were not significant (F (1, 14)
= 4.016, p = 0.065 for CLZ 5.0 mg/kg; F (1, 14) = 1.901, p = 0.190 for CLZ 2.5 mg/kg), nor
did the interaction between the group and test day, all ps > 0.723. However, planned two
group comparisons on each test day did show that the CLZ 5.0-CLZ 5.0+PCP group had
higher motor activity than the VEH-CLZ 5.0+PCP group on day 5, p = 0.045, indicating an
even slower emergence of CLZ tolerance at this dose.
The original CLZ tolerance was dose-dependently expressed in the CAR
model—Figure 4 shows the number of avoidance responses during the CS-only, retraining,
and tolerance retest sessions in the CAR. No main effect of group was found on the CS-only
session, F (7, 57) = 1.448, p = 0.205, or on the retraining session, F (7, 57) = 0.482, p =
0.844 (Fig. 4A). One-way ANOVA on the tolerance retest session showed a main effect of
group, F (7, 57) = 7.125, p < 0.001 (Fig. 4B). Post hoc tests indicated that the two CLZ 5.0
and CLZ 10.0 groups (i.e. one treated with CLZ in both CAR and PCP models and one
treated with CLZ only in the PCP model) made significantly more avoidances than the
corresponding CLZ-naïve group (VEH-VEH+PCP group), p < 0.05, confirming the CLZ
tolerance.
3.2. Experiment 2: Transferability of CLZ-induced tolerance effect from the PCP
hyperlocomotion model to the CAR model and back to the PCP model
Repeated CLZ treatment decreased PCP-induced hyperlocomotion—On the
habituation day, all rats were placed in the motor activity boxes for 30 min with no drug
treatment. One-way ANOVA showed no main effect of group, F (2, 41) = 0.089, p = 0.915,
indicating there was no significant difference among the three groups on spontaneous motor
activity (data not shown).
Figure 5A shows that motor activity recorded in the first 30 min test period (as measured
after CLZ but before PCP injection). A split-plot ANOVA followed by post hoc tests
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showed that the CLZ 5+PCP group had significantly lower motor activity than the VEH
+VEH group and the VEH+PCP group throughout the 5 test days, ps < 0.05.
Figure 5B shows the mean motor activity of the rats that received CLZ 5.0 mg/kg or vehicle
treatment during the 60 min test period after saline or PCP injection across the five drug
conditioning days. Repeated PCP treatment (1.6 mg/kg, sc) progressively increased motor
activity across the five days. CLZ did not inhibit PCP-induced hyperlocomotion until the
second day of testing and maintained its inhibition throughout. A split-plot ANOVA
revealed a main effect of group, F (2, 41) = 29.438, p < 0.001, a main effect of test day, F
(4,164) = 4.031, p = 0.004, and a significant group × test day interaction, F (8,164) = 8.077,
p < 0.001. Post hoc tests showed that the VEH+PCP group had a significantly higher motor
activity than the other groups, ps < 0.001. The VEH+PCP group made more motor activity
than the other two groups on every test day, ps < 0.001, except on day 1 when the CLZ
5.0+PCP and VEH+PCP groups did not differ significantly from each other, p = 1.000.
CLZ tolerance manifested itself in the CAR model on the first day, but
diminished throughout the repeated test period—One day before the tolerance
expression test in the CAR model, rats were given a CAR retraining session to bring their
avoidance back to the pre-drug level. Figure 6A shows the mean number of avoidance
responses during the retraining and the first day of tolerance expression test in the CAR. On
the retraining day, all groups had a high level of avoidance responding and there was no
significant group difference, F (4, 39) = 2.097, p = 0.100. On the first day of tolerance
expression test, one-way ANOVA revealed a main effect of group, F (4, 39) = 32.976, p <
0.001. Post hoc tests revealed that all three groups that were treated with CLZ had
significantly lower avoidances than the two groups treated with vehicle (i.e. the VEH+VEH
+VEH group, ps < 0.001 and VEH+PCP+VEH group, ps < 0.001). More importantly, the
group that had been previously treated with CLZ in the PCP model (i.e. CLZ 5.0+PCP-CLZ
5.0) made significantly more avoidances than the two groups that received CLZ for the first
time (i.e. VEH+VEH-CLZ 5.0 and VEH+PCP-CLZ 5.0), ps < 0.05 indicating that prior CLZ
treatment in the PCP model induced a tolerance which extended to the CAR model on the
first day of testing.
Throughout the 5 days of testing, the two vehicle groups showed a slight but significant
decline in avoidance responding (Fig. 6B). A split-plot ANOVA revealed a main effect of
test day, F (4, 60) = 7.529, p < 0.001, but no main effect of group, F (1, 15) = 0.203, p =
0.659. A split-plot ANOVA was also conducted to examine the possible group difference
among the three CLZ treated groups (Fig. 6C). There was a main effect of test day, F (4, 96)
= 4.023, p = 0.005, a significant test day × group interaction, F (4, 96) = 2.299, p = 0.027,
but no main effect of group, F (2, 24) = 1.524, p = 0.238. One-way ANOVA on each test
day showed no main effect of group except on test day 1, p = 0.039. These findings
suggested that CLZ tolerance induced in the PCP hyperlocomotion model was manifested in
the CAR model on the first day, but this effect diminished throughout the 5 test days.
The original CLZ tolerance was expressed in the PCP model, but the new
tolerance induced in the CAR model did not express in the PCP
hyperlocomotion model—In the final tolerance expression retest in the PCP model, all
rats received the first injection of CLZ 5.0 mg/kg followed by PCP 1.6 mg/kg injection 30
min later. Figure 7A shows that motor activity recorded in the first 30 min test period (as
measured after CLZ but before PCP injection). One-way ANOVA showed no main effect of
group, F (4, 39) = 2.165, p = 0.091. In the last 60 min of testing after PCP injection (Fig.
7B), rats that were previously treated with CLZ in the PCP model (i.e. CLZ 5.0+PCP-CLZ
5.0 group) exhibited a higher level of motor activity than the other groups. One-way
ANOVA showed a main effect of group, F (4, 39) = 2.777, p = 0.040. Post hoc tests showed
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that the CLZ 5.0+PCP-CLZ 5.0 group differed significantly from the VEH+VEH-VEH
group, ps < 0.046, and differed marginally from the VEH+PCP-VEH group, p = 0.077,
indicating a CLZ tolerance effect. The findings that the VEH+PCP-CLZ 5.0 group did not
differ from the VEH+PCP-VEH, p = 0.985, and the VEH+VEH-CLZ 5.0 group did not
differ from the VEH+VEH-VEH, p = 0.987, strongly suggest that CLZ tolerance putatively
induced in the CAR model did not extend immediately to the PCP hyperlocomotion model.
This finding is consistent with the one reported in Experiment 1 (Fig. 2B).
4. Discussion
The present study used an across-model transfer paradigm and examined the contextual and
behavioral controls of the expression of CLZ tolerance. Table 3 summarizes the two patterns
of CLZ tolerance expression in the CAR and PCP hyperlocomotion models.
Repeated CLZ treatment disrupted avoidance response in a dose-dependent fashion and
decreased PCP-induced hyperlocomotion persistently throughout the drug treatment period
(the induction phase) (Fig. 1 and 5B). These findings are consistent with our previous
findings [11, 13, 23, 24] as well as others [20, 29, 30]. Our previous work also shows that
repeated administration of haloperidol, olanzapine or risperidone induces a sensitization
effect in both the induction and expression phases [1, 10, 11, 13, 23, 25, 31, 32]. CLZ differs
from these antipsychotics in this regard, as prior CLZ exposure actually induced a tolerance
effect in the original model where repeated CLZ took place, and this tolerance effect only
manifested in the expression phase, but not in the induction phase. This finding suggests that
the expression of CLZ tolerance does not necessarily require the manifestation of such a
tolerance during the induction phase. The induction and expression of CLZ tolerance may
involve different processes and mechanisms that affect ongoing behaviors differentially. A
similar pattern has been reported for other psychotropic drugs [33]. Alternatively, the lack of
sign of tolerance development in the induction phase may indicate that the experimental
condition allowing its appearance is not optimal. In fact, our unpublished observation shows
that CLZ tolerance does appear in the induction phase when rats are tested under the typical
CS (sound)-US (shock) condition.
The present study focuses on the possible impact of environmental stimuli and behavioral
variables on the expression of CLZ tolerance. To the best of our knowledge, there has ever
only been one study that has implicitly addressed this issue. Sanger (1985) compared two
groups of rats treated with CLZ (20 mg/kg, ip) in a CAR model. The first group was given
CLZ 30 min before each of the four daily avoidance test sessions, while the second group
was given CLZ immediately after the first three sessions and 30 min before the fourth
session. He found that rats in the first group showed disrupted avoidance responding in the
first two sessions, but no disruption in the last two sessions. Interestingly, rats in the second
group also showed no disruption of avoidance when CLZ was given before the fourth
session, despite the fact that they received CLZ in the first three sessions outside the CAR
testing apparatus. This finding implies that CLZ tolerance is independent of context such
that contextual cues and behavioral response have little impact on its induction and
expression. Our results indicate that this conclusion is too simplistic and may be limited to
the CAR model. In Experiment 2, we observed that rats previously treated with CLZ in the
PCP model (i.e. CLZ 5.0+PCP-CLZ 5.0) made significantly more avoidances than rats that
received CLZ for the first time (i.e. VEH+VEH-CLZ 5.0 and VEH+PCP-CLZ 5.0) (Fig.
6A), a sign of CLZ tolerance in agreement with that from Sanger (1985). However, results
from Experiment 1 (Fig. 2 and 3) clearly show that it is not always the case: CLZ tolerance
induced in the CAR model did not express immediately in the PCP-induced
hyperlocomotion model and emerged only after several days of testing.
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The present study significantly advances the study of CLZ tolerance by providing a novel
approach to assess contextual and behavioral controls of this phenomenon. Studies on
contextual controls of behavioral tolerance typically compare a “before” group (a group that
receives drug injection in the test environment) with an “after” group (a group that receives
vehicle injection in the test environment, and drug in the home cage) in a single model
paradigm utilizing a “before-and-after” technique [34], as employed by Sanger (1985). The
contextual controls of tolerance is indicated by the finding that it is expressed only in the
“before” group but not in the “after” group [35]. The across-model transfer approach
complements this traditional technique in testing both CLZ experienced and naïve groups
(e.g. in the CAR model) were tested under the drug in the new model (e.g. in the PCP
model) for the first time during the tolerance expression test. Because the across-model
transfer paradigm utilizes two behavioral responses that are topographically different and
appear in two distinct test environments, and encompasses changes in contextual cues and
behavioral responses, this approach provides a more reliable assessment of contextual and
behavioral controls of CLZ tolerance. Future work interested in the neurobiological
mechanisms underlying the contextual and behavioral controls of CLZ tolerance could
benefit from this approach.
One of the interesting findings was the different time courses of across-model expression of
CLZ tolerance. CLZ tolerance induced in the CAR did not manifest itself in the PCP
hyperlocomotion model on the first day, but emerged after 5 days of testing. In contrast,
CLZ tolerance induced in the PCP hyperlocomotion model manifested itself in the CAR
model on the first day, but decreased over the treatment period. Substantial evidence
suggests that contextual cues, especially the environmental stimuli and interoceptive drug
state can serve as conditioned stimuli (CS) and become associated with unconditional drug
effects (as US) via a Pavlovian conditioning process after being repeatedly paired with a
drug [36]. Anagnostaras and Robinson (1996) as well as others [37, 38] suggest that
contextual cues and interoceptive drug states can also act as occasion-setters to modulate the
expression of psychomotor sensitization. Based on these findings, we postulate that the
distinct time courses reflect differential impacts of contextual cues and behaviors on the
expression of CLZ tolerance. In addition, we suggest that contextual cues and different
behavior responses may influence the rate at which CLZ tolerance develops, rather than
affect the development of tolerance itself [34]. It is possible that distinct contextual cues
(e.g. environmental stimuli, interoceptive drug cue, etc) and altered behavioral responses in
each model may develop a different strength of association with pharmacological actions of
CLZ via a Pavlovian conditioning process and thus acquire the ability to modulate its
induction and expression [39–42]. Furthermore, the CS-elicited shuttling response in the
CAR model may have a stronger influence (i.e. occasion-setting capacity) on CLZ tolerance
development than PCP-induced locomotion in the test cages. This explains the findings that
tolerance that developed in the PCP model extended immediately to the CAR model,
whereas tolerance that developed in the CAR model did not immediately extend to the PCP
model.
One fundamental issue is the exact neurobiological mechanisms responsible for CLZ
tolerance and associated situational specificity. Our recent work on the neurochemical basis
of CLZ tolerance in the CAR model implicates a role for dopamine D2/3 receptors [11]. We
found that pretreatment of quinpirole, a selective D2/D3 dopaminergic receptor agonist,
enhanced CLZ tolerance effect, suggesting that the induction of CLZ tolerance effect may
be mediated by D2/D3 blockade-initiated neural processes. The involvement of dopamine
receptor-mediated processes in CLZ tolerance is also supported by early findings showing
that repeated CLZ treatment leads to a suppressed firing (i.e. depolarization inactivation) of
dopamine neurons in the ventral tegmental area but not in the substantia nigra and a
suppressed release of dopamine in the nucleus accumbens but not in the striatum [43, 44].
Feng et al. Page 10
Behav Brain Res. Author manuscript; available in PMC 2014 February 01.
$watermark-text
$watermark-text
$watermark-text
Since CLZ also acts on many other receptors (e.g. 5-HT2A/2C, D1, D3, α1-noradrenergic,
etc), of which some have been implicated in CLZ tolerance [45–47], future work should
systematically investigate the role of these receptors in the mediation of CLZ tolerance and
its contextual and behavioral controls.
The present study illustrates the power of environmental and behavioral variables on the
expression of CLZ tolerance. Given the poverty of our current understanding of CLZ
tolerance and its contextual and behavioral controls, it is clearly premature to speculate on
its clinical relevance. Nevertheless, as CLZis administered repeatedly to patients with
schizophrenia for a prolonged period of time, CLZ tolerance seems to be an inevitable
feature of the treatment. Previous work suggests that CLZ tolerance isre lated to the
withdrawal symptoms seen with the discontinuation of CLZ use (e.g. nausea, vomiting,
insomnia, diarrhoea, agitation, aggression, headache, etc) [48] and relapse to psychosis [49,
50]. Thus the environmental and behavioral controls of its induction and expression as
evidenced in these two preclinical tests may indicate that the appearance of CLZ withdrawal
syndromes is also subjected to the same modulation by various environmental and
behavioral factors. If CLZ withdrawal syndrome and CLZ withdrawal-induced rapid relapse
to psychosis were behavioral signs to be avoided in patients, understanding how these
factors play a role in the induction and expression of CLZ tolerance may greatly enhance our
understanding of its clinical treatment effects as well as possible side effects.
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Research Highlights
• Repeated clozapine treatment caused a tolerance effect in the avoidance
conditioning model.
• Repeated clozapine treatment also caused a tolerance effect in the PCP
hyperlocomotion model.
• The transfer of clozapine tolerance from one model to another is situational
specific and time-dependent.
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Figure 1.
Effect of repeated CLZ treatment (2.5, 5.0 and 10.0mg/kg, sc, −60min) on conditioned
avoidance response. Number of avoidance responses made by the rats in the four groups on
the last training day and during the five drug test sessions. *p < 0.001 in comparison to the
VEH group; #p < 0.05, ##p ≤ 0.001 in comparison to the CLZ 2.5 group.
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Figure 2.
Effect of prior CLZ treatment in the CAR model on the PCP-induced hyperlocomotion. (A)
Motor activity was measured for the 30 min after CLZ or vehicle injection and
expressed as mean number of photobeam breaks for each group. (B) Motor activity was
measured for 60 min after vehicle or PCP (1.6 mg/kg) injection and expressed as mean
number of photobeam breaks for each group. *p < 0.05 in comparison to the VEH-VEH
+VEH group; #p < 0.05 in comparison to the VEH-VEH+PCP group.
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Figure 3.
Effect of prior CLZ treatment in the CAR model on the PCP-induced hyperlocomotion.
Motor activity was measured for the 60 min after vehicle or PCP (1.6 mg/kg) injection and
expressed as mean number of photobeam breaks for each group across the five CLZ
tolerance expression test days. (A) Two group comparison between the PCP and vehicle
groups. (B) Two group comparison between the two low dose CLZ groups (2.5 mg/kg). (C)
Two group comparison between the two medium CLZ dose groups (5.0 mg/kg). (D) Two
group comparison between the two high dose CLZ groups (10.0 mg/kg). *p < 0.05 in
comparison to the corresponding groups.
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Figure 4.
Effect of CLZ (5.0mg/kg, sc, −60min) challenge on conditioned avoidance response in the
CLZ tolerance expression retest. (A) Number of avoidance responses made by rats during
the CS-only and retraining sessions. (B) Number of avoidance responses made by the rats in
the CLZ tolerance expression retest. *p<0.05 in comparison to the VEH-VEH+VEH
group; #p < 0.05, ##p < 0.001 in comparison to the VEH-VEH+PCP group.
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Figure 5.
Effect of repeated CLZ treatment (5.0 mg/kg, sc) on the PCP-induced hyperlocomotion
across the five drug test sessions. (A) Motor activity was measured for the 30 min after
CLZ or vehicle injection and expressed as mean number of photobeam breaks for each
group. (B) Motor activity was measured for the 60 min after vehicle or PCP (1.6 mg/kg)
injection and expressed as mean number of photobeam breaks for each group. *p < 0.05, **p
< 0.001 in comparison to the VEH+VEH group; #p < 0.05, ##p < 0.001 in comparison to the
VEH+PCP group.
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Figure 6.
Effect of prior CLZ treatment in the PCP-induced hyperlocomotion model on avoidance
response (tolerance expression test). Number of avoidance responses made by the rats were
recorded after CLZ injection (5.0mg/kg, sc, −60min). (A) Number of avoidance responses
made by the rats during the retraining and the first CLZ tolerance expression test day in the
CAR model. $p<0.001 in comparison to the VEH+PCP-VEH group; *p<0.001 in
comparison to the VEH+VEH-VEH group; #p<0.05 in comparison to the CLZ 5.0+PCP-
CLZ 5.0 group. (B) Two group comparison between the vehicle group and PCP group
across the five CLZ tolerance expression test days. (C) Three group comparison among the
three CLZ groups across the five test days.
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Figure 7.
Effect of CLZ (5.0mg/kg, sc) challenge on the PCP-induced hyperlocomotion in the CLZ
tolerance retest. (A) Motor activity was measured for the 30 min after CLZ or vehicle
injection and expressed as mean number of photobeam breaks for each group. (B)
Motor activity was measured for 60 min after vehicle or PCP (1.6 mg/kg) injection and
expressed as mean number of photobeam breaks for each group. *p<0.05 in comparison to
the CLZ 5.0+PCP-CLZ 5.0 group.
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Table 1
A schematic depiction of the experimental procedure and groups in Experiment 1.
CAR: conditioned avoidance response; CLZ: clozapine; PCP: phencyclidine; VEH: vehicle.
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Table 2
A schematic depiction of the experimental procedure and groups in Experiment 2.
CAR: conditioned avoidance response; CLZ: clozapine; PCP: phencyclidine; VEH: vehicle.
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Table 3
A summary of the expression of clozapine tolerance in the across-model transfer paradigm.
Start condition Tolerance Test Tolerance retest
CAR (5 days)→ PCP (5 days) CAR (1 day)
CLZ tolerance does not express on the first day but emerges over time CLZ tolerance is detected
PCP (5 days)→ CAR (5 days) PCP (1 days)
CLZ tolerance expresses on the first day but decreases over time CLZ tolerance is detected
CAR: conditioned avoidance response; CLZ: clozapine; PCP: phencyclidine.
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